Aquilo refers to the Roman god of the northern wind. Located in the northern part of the Netherlands, our aim is to contribute to therapies directed at airflow improvement in lung diseases. We are a spin-off company from the University of Groningen, specialized in asthma, COPD and lung fibrosis pharmacology. We have different well-validated pre-clinical models available to study the effects of your compound, including in vitro, ex vivo and in vivo models. We use several techniques to analyze efficacy of your compound or therapy, including lung function assessment, RT-qPCR, histology, analysis of organoid proliferation and differentiation and omics analyzes. Futhermore, we have experience with functioning as a core lab for multi-center clinical trials.
Recent posts
- Rho-Kinase 1/2 Inhibition Prevents Transforming Growth Factor-β-Induced Effects on Pulmonary Remodeling and RepairJanuary 21, 2021 - 7:53 pm
Wu X, Verschut V, Woest ME, Ng-Blichfeldt JP, Matias A, Villetti G, Accetta A, Facchinetti F, Gosens R, Kistemaker LEM. Front. Pharmacol., 20 January 2021. Publication: https://www.frontiersin.org/articles/10.3389/fphar.2020.609509/full Abstract Transforming growth factor (TGF)-β-induced myofibroblast transformation and alterations in mesenchymal-epithelial interactions contribute to chronic lung diseases such as chronic obstructive pulmonary disease (COPD), asthma and pulmonary fibrosis. […]
Contact us
Aquilo
Antonius Deusinglaan 1, XB10
9713 AV Groningen
Phone: 0031 (0) 50 363 6372
Fax: 0031 (0) 50 363 6908
Email info@aquilo.nl
CoC id: 63635666
Tax id: NL.8553.26.396.B.01